(Q83322982)
Statements
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age (English)
R Baxter
P A Patriarca
K Ensor
R Izikson
K L Goldenthal